About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AAFA Statement in Response to AstraZeneca Asthma Inhaler Cost Announcement

By: via GlobeNewswire

Washington, DC, March 18, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) welcomes efforts to make asthma medicines more affordable and accessible. AAFA continues to lead advocacy efforts to change the drug pricing ecosystem on behalf of the 27 million people in the United States with asthma.  

AstraZeneca announced it will cap out-of-pocket costs for its entire U.S. inhaled respiratory portfolio at $35 per month for patients who have commercial insurance or no insurance.  

"AAFA applauds AstraZeneca’s announcement to cap costs of asthma inhalers and urges other manufacturers to take similar steps to make medications more affordable and accessible,” said AAFA President and CEO Kenneth Mendez. “AAFA continues to raise the voice of the patient community and draw attention to the ways America’s complex drug pricing ecosystem makes asthma medications more expensive for people who need them most. Drug manufacturers, pharmacy benefit managers, insurers, employers, and the government operate in a perverse system that drives prices higher—and all stakeholders must work together to improve affordability and access.” 

Access to affordable drugs is a critical component of reducing racial disparities in asthma. Black and Hispanic individuals not only experience higher rates of asthma but also are more likely to be uninsured or underinsured. Deaths due to asthma—although decreasing overall—occur at a much higher rate in the Black and Puerto Rican populations than in the White population. Black individuals are nearly three times as likely to die from asthma than White individuals.  

Last fall, AAFA shared patient stories and its Asthma Disparities in America report with the Senate Health, Education, Labor, and Pensions (HELP) Committee which then launched an investigation into the high price of asthma inhalers early this year. 

AAFA’s research indicates that when the cost of medicine becomes a barrier to treatment, people with asthma resort to rationing or simply discontinue use. 

Access to asthma medications can save lives, reduce hospitalizations, and lower the more than $82 billion in annual costs to the U.S. economy from this chronic disease. But the U.S. health care system is complex and often leaves patients with few affordable options.  

## 

About AAFA 
Founded in 1953, AAFA is the oldest and largest non-profit patient organization dedicated to saving lives and reducing the burden of disease for people with asthma, allergies, and related conditions through research, education, advocacy, and support. AAFA offers extensive support for individuals and families affected by asthma and allergic diseases, such as food allergies and atopic dermatitis (eczema). Through its online patient support communities, network of regional chapters, and collaborations with community-based groups, AAFA empowers patients and their families by providing practical, evidence-based information and community programs and services. AAFA is the only asthma and allergy patient advocacy group that is certified to meet the standards of excellence set by the National Health Council. For more information, visit: aafa.org 


Andy Spears
Asthma and Allergy Foundation of America
2029741223
media@aafa.org

More News

View More
3 Defensive Stocks to Buy as Economic Uncertainty Lingers
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers CLX COST CVX
3 Dividend Hikes That Signal Renewed Strength in 2025
Via MarketBeat
Topics Economy
Tickers ACN F GE GM HON THO
3 Sustainable Stocks Benefiting From the AI Energy Surge
Via MarketBeat
Topics Artificial Intelligence Economy Government
Tickers HUBB NEE XYL
NVIDIA Analysts Lift Targets: What It Means for the Stock Price
Via MarketBeat
Topics Artificial Intelligence
Tickers NVDA
Fastenal Stock Pulls Back in October—Is It Time to Buy FAST?
Via MarketBeat
Tickers FAST
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.